Value, Affordability, and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based.
Incentives for R&D: Payment Options and Pricing Challenges
8 January 2020
The issue of rising prescription drug prices is a concern in every country. Dozens of policy initiatives and hundreds of research projects over last the fifty…
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
8 January 2020
Histology independent therapies, a new class of medicines that target cancer based on specific genomic or molecular alterations of cancer cells rather than tissue of origin,…
Funding Challenges in the Malaysian Health Care System
7 January 2020
Adrian Towse presented at the Monash Malaysia Health Economics Forum 2019 on three related topics: health system financing in Malaysia; pharmaceutical price regulation and competition in…
NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?
7 January 2020
The National Institute of Health and Care Excellence (NICE) makes recommendations for the use of interventions including medicines in the National Health Service in England based…
A Bargaining Approach: A Theory on ICER Pricing and Optimal Level of Cost-Effectiveness Threshold
1 July 2020
This paper presents a supply and demand model of pharmaceutical markets to analyse the relationship between the value of the Cost-Effectiveness Threshold (CET) and the distribution…
International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making
5 January 2020
OHE presents an overview on the use of cost-effectiveness thresholds (CETs) in a number of selected countries in their decision-making process for health technology assessments (HTAs).…
Indication-Based Pricing (IBP) Consultation Report
1 April 2020
Although the science underlying drug development has evolved, there has been little change in how we pay for them. As more and more medicines come to…
Meningococcal Vaccines: An International Comparison of Decision-Making Processes, Frameworks and Methodologies. Are Values Missing?
3 January 2020
Meningococcal disease is a life-threatening infection and can result in severe sequelae. Recent scientific and technical advances have led to the discovery and implementation of novel…
OHE at HESG Winter 2020
2 January 2020
Meet some of the OHE team at the Health Economists’ Study Group (HESG) Winter 2020 meeting in Newcastle, 6-8 January 2020.